腫瘍循環器診療ハンドブック

出版社： メジカルビュー社
著者：
発行日： 2020-11-30
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784758319669
電子書籍版： 2020-11-30 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,720 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,720 円(税込)

購入する
特記事項：

商品紹介

がん患者の心血管死を防ぐために，最新の知識を網羅し，診療のスタンダードを解説！

目次

  • ■基礎編
    1 章　「腫瘍循環器学」時代のがん診療・管理とは
    　1　いま，なぜ腫瘍循環器なのか－腫瘍専門医の立場から
    　2　いま，なぜ腫瘍循環器なのか－循環器専門医の立場から
    2 章　がん治療による心血管合併症の基礎知識（病態生理と疫学）
    　1　心機能障害/心不全
    　2　虚血性心疾患
    　3　心筋炎
    　4　高血圧症
    　5　不整脈
    　6　末梢動脈疾患（動脈硬化性疾患）
    　7　肺高血圧症
    　8　放射線療法による心血管合併症
    3 章　がん種に関連する心血管合併症の基礎知識（病態生理と疫学）
    　1　がん関連血栓症（CAT）
    　2　肺腫瘍血栓性微小血管症（PTTM）
    　3　がん性心タンポナーデ
    　4　心臓腫瘍

    ■実践編
    4 章　がん診療で求められるCTRCD のマネジメント
    　1　心血管合併症のリスク評価
    　2　循環器専門医へのコンサルトのタイミング
    　3　がん治療薬の減量・休薬・中止の判断
    　4　がん治療関連心機能障害（CTRCD）の診療アルゴリズム
    　5　免疫チェックポイント阻害薬による心筋症の診療アルゴリズム
    　6　がん関連静脈血栓塞栓症の診療アルゴリズム
    5 章　心血管合併症への注意事項（がん種別）
    　1　白血病
    　2　悪性リンパ腫
    　3　多発性骨髄腫
    　4　乳がん
    　5　上部消化管がん
    　6　下部消化管がん
    　7　肝胆膵がん　
    　8　肺がん
    　9　脳腫瘍
    　10 甲状腺がん・頭頸部がん
    　11 泌尿器系がん
    　12 婦人科がん
    　13 希少がん・肉腫
    6 章　循環器診療で求められるCTRCD のマネジメント
    　1　がん治療関連心機能障害（CTRCD）の予防と治療
    　2　免疫チェックポイント阻害薬による心筋炎の治療
    　3　がん患者における降圧治療　
    　4　がん関連静脈血栓塞栓症の抗凝固療法
    7 章　循環器系検査でわかること
    　1　心電図
    　2　心エコー図
    　3　心筋バイオマーカー
    　4　画像診断（心臓MRI，心臓核医学，心臓CT）
    　5　心筋生検
    　6　下肢静脈エコー
    　7　凝固線溶系バイオマーカー
    　8　血管機能検査
    8 章　腫瘍循環器診療における連携のコツと工夫
    　1　腫瘍循環器診療における連携のコツ
    　2　多職種連携
    　3　腫瘍循環器外来の取り組み
    　4　診療科連携
    　5　腫瘍循環器リハビリテーション（CORE）
    　6　小児の移行期医療における連携
    　7　AYA世代の診療における連携
    　8　高齢者における連携
    　9　妊娠・産褥期における連携
    　10 終末期医療における連携

    ■付録
    　1　有害事象共通用語規準（CTCAE）における心血管合併症一覧
    　2　がん治療薬による心血管合併症一覧
    　3　心電図の正常値と典型的な不整脈
    　4　心エコー図検査の正常値
    　5　冠動脈造影のAHA分類
    　6　Swan-Ganzカテーテル検査
    　7　抗腫瘍薬と循環器治療薬の相互作用一覧
    　8　腫瘍循環器領域の主な情報の入手先（学会，ガイドライン，HPなど）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

基礎編

P.3 掲載の参考文献
1) Armenian S, Bhatia S : Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ Book 38 : 3-12, 2018.
PubMed
2) Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al : Late Cardiotoxicity After Treatment for Hodgkin Lymphoma. Blood 109 : 1878-1886, 2007.
PubMed
3) Maraldo MV, Giusti F, Vogelius IR, et al : European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group : Cardiovascular disease after treatment for Hodgkin's lymphoma : an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2 : e492-502, 2015.
PubMed
P.7 掲載の参考文献
1) Shapiro CL : Cancer Survivorship. N Engl J Med 379 : 2438-2450, 2018.
PubMed
2) Mayer DK, Nasso SF, Earp JA et al : Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol 18 : e11-e18, 2017.
PubMed
3) 佐瀬一洋ほか : がんサバイバーに対する循環器サポートの必要性. 循環器内科 83 : 495-503, 2018.
 
4) Armstrong GT, Chen Y, Yasui Y, et al : Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med 374 : 833, 2016.
PubMed
5) Abdel-Qadir H, Austin PC, Lee DS, et al : A population-based study of cardiovascular mortality follow-in early-stage breast cancer. JAMA Cardiol 2 : 88-93, 2017.
PubMed
6) Lenneman CG, Sawer DB : Cardio-Oncology : An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res 118 : 1008-1020, 2016.
 
7) Herrmann J : Adverse cardiac effects of cancer therapies : cardiotoxicity and arrhythmia. Nat Rev Cardiol 17 : 474-502, 2020.
PubMed
8) Herrmann J : Vascular toxic effects of cancer therapies. Nat Rev Cardiol 17 : 503-522, 2020.
PubMed
9) Kenigsberg B, Wellstein A, Barac A : Left Ventricular Dysfunction in Cancer Treatment : Is it Relevant? JACC Heart Fail 6 : 87-95, 2018.
PubMed
10) Shinano H, Miyazaki S, Miura K, et al : Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab. Circ Rep 2 : 235-242, 2020.
PubMed
11) Mehta LS, Watson KE, Barac A, et al : Cardiovascular Disease and Breast Cancer : Where These Entities Intersect. A Scientific Statement from the American Heart Association. Irculation 137 : e30-e66, 2018.
 
12) Ky B : Cardio-Oncology. In : Zipes DP, Libby P, Bonow RO, et al (eds). Braunwald's Heart Disease, 11th ed. Elsevier, Philadelphia, 2018, p.1641-1650.
 
13) Shelburne N, Simonds NI, Adhikari B, et al : Changing Hearts and Minds : Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep 21 : 9, 2019.
PubMed
14) Levis BE, Binkley PF, Shapiro CL : Cardiotoxic effects of anthracycline-based therapy : what is the evidence and what are the potential harms? Lancet Oncol 18 : e445, 2017.
PubMed
15) Armenian SH, Hudson MM, Mulder RL, et al : Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16 : e123-e136, 2015.
PubMed
16) Armenian SH, Lacchetti C, Barac A, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancer : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
17) 佐瀬一洋ほか : Cardio-Oncology-最新の診療ガイドラインと今後の課題-. 腫瘍内科 22 : 181-189, 2018.
 
18) Campia U, Moslehi JJ, Amiri-Kordestani L, et al : Cardio-Oncology : Vascular and Metabolic Perspectives : A Scientific Statement from the American Heart Association. Circulation 139 : e579-e602, 2019.
PubMed
19) Key NS, Khorana AA, Kuderer NM, et al : Venous firomboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 38 : 496-520, 2019.
PubMed
20) Gilchrist SC, Barac A, Ades PA, et al : Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors : A Scientific Statement from the American Heart Association. Circulation 139 : e997-e1012, 2019.
PubMed
21) Sase K, Kida K, Furukawa Y, et al : Cardio-Oncology rehabilitation-challenges and opportunities to improve cardiovascular outcomes in cancer patients and survivors. J Cardiol 2020 : S0914-5087 (20) 30255-0. doi : 10. 1016/j.jjcc. 2020. 07. 014〔Online ahead of print〕.
 
22) 藤原康弘, 佐瀬一洋, 向井幹夫 : がんと循環器診療の融合をめざす新たな学際領域 Cardio-Oncology. 週刊医学界新聞 3265 : 1-2, 2018.
 
P.9 掲載の参考文献
1) Zamorano JL, Lancellotti P, Munoz DR, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
2) Curigliano G, Lenihan L, Fradley M, et al : Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 31 : 171-190, 2020.
 
P.11 掲載の参考文献
1) Armenian SH, Lacchetti C, Barac A, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
2) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
3) Zhang S, Liu X, Bawa-Khalfe T, et al : Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18 : 1639-1642, 2012.
PubMed
4) Cardinale D, Colombo A, Bacchiani G, et al : Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 : 1981-1988, 2015.
PubMed
P.13 掲載の参考文献
1) Zeglinski M, Ludke A, Jassal DS, Singal PK : Trastuzumab-induced cardiac dysfunction : A 'dual-hit'. Exp Clin Cardiol 16 : 70-74, 2011.
PubMed
2) Nemeth BT, Varga Z, Wu WJ, Pacher P : Trastuzumab cardiotoxicity : from clinical trials to experimental studies. Br J Pharmacol 174 : 3727-3748, 2017.
PubMed
3) Seferina SC, de Boer M, Derksen MW, et al : Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily dutch practice : a study of the southeast netherlands breast cancer consortium. Oncologist 21 : 555-562, 2016.
 
4) Tan-Chiu E, Yothers G, Romond E, et al : Assesment of Cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by Paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer : NSABP B-31. J Clin Oncol 23 : 7811-7819, 2005.
PubMed
5) Ezaz G, Long JB, Gross CP, Chen J : Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3 : e000472, 2014.
PubMed
P.15 掲載の参考文献
1) Moslehi JJ : Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 : 1457-1467, 2016.
PubMed
2) Totzeck M, Mincu RI, Mrotzek S, et al : Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity : a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol 25 : 482-4940, 2018.
PubMed
3) Li W, Croce K, Steensma DP, et al : Vascular and metabolic implications of novel targeted cancer therapies. J Am Coll Cardiol 66 : 1160-1178, 2015.
PubMed
4) Robinson ES, Khankin EV, Karumanchi SA, et al : Hypertension induced by VEGF signaling pathway inhibition : mechanisms and potential use as a biomarker. Semin Nephrol 30 : 591-601, 2010.
PubMed
P.17 掲載の参考文献
1) Fu HY, Mukai M, Awata N, et al : Protein quality control dysfunction in cardiovascular complications induced by anti-cancer drugs. Cardiovasc Drugs Ther 31 : 109-117, 2017.
PubMed
P.20 掲載の参考文献
1) Got tdiener JS, Appelbaum FR, Ferrans VJ, et al : Cardiotox i c ity assoc iated wi th high-dose cyclophosphamide therapy. Arch Intern Med 141 : 758-763, 1981.
 
2) Rowinsky EK, McGuire WP, Guarnieri T, et al : Cardiac disturbances during the administration of taxol. J Clin Oncol 9 : 1704-1712, 1991.
PubMed
3) Peng J, Dong C, Wang C, et al : Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients : a prospective study. Cancer Commun (London) 38 : 22, 2018.
 
4) Herrmann J : Adverse cardiac effects of cancer therapies : cardiotoxicity and arrhythmia. Nat Rev Cardiol 17 : 474-502, 2020.
PubMed
5) Ganatra S, Sharma A, Shah S, et al : Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol 4 : 1491-1500, 2018.
PubMed
P.23 掲載の参考文献
1) Handy CE, Quispe R, Pinto X, et al : Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment : together we are stronger. Circulation 138 : 727-734, 2018.
PubMed
2) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
3) Elkeles A : Cancer and atherosclerosis. Br J Cancer 10 : 247-250, 1956.
PubMed
4) Tabata N, Sueta D, Yamamoto E, et al : Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention : a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes 4 : 290-300, 2018.
PubMed
5) Tabata N, Sueta D, Yamamoto E, et al : A retrospective study of arterial stiffnesss and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. J Hypertens 37 : 754-764, 2019.
 
6) Sueta D, Tabata N, Ikeda S, et al : Differential predictive factors for cardiovascular events in patients with or without cancer history. Medicine (Baltimore) 98 : e17602, 2019.
PubMed
7) Cummings JH, Bingham SA : Diet and the prevention of cancer. BMJ 317 : 1636-1640, 1998.
PubMed
8) Sueta D, Hokimoto S, Utsunomiya D, et al : New aspects of onco-cardiology. Int J Cardiol 206 : 68-70, 2016.
PubMed
9) Libby P, Ebert BL : CHIP (clonal hematopoiesis of indeterminate potential) : Potent and newly recognized contributor to cardiovascular risk. Circulation 138 : 666-668, 2018.
PubMed
10) Li M, Cima MJ, Milner DA, Jr : If it's not one thing, it's another : An inverse relationship of malignancy and atherosclerotic disease. PLoS One 10 : e0126855, 2015.
 
P.26 掲載の参考文献
1) Johnson DB, Balko JM, Compton ML, et al : Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375 : 1749-1755, 2016.
PubMed
2) Salem JE, Manouchehri A, Moey M, et al : Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol 19 : 1579-1589, 2018.
 
P.29 掲載の参考文献
1) 三好千春ほか : 腫瘍の増殖過程における血管新生. 日本バイオレオロジー学会誌 15 : 146-155, 2001.
 
2) 小室一成ほか : 実践Onco-Cardiology. 中外医学社, 東京, 2018, pp.51-52.
 
3) 室原豊明 : 分子標的薬による心血管障害. 心臓 49 : 812-815, 2017.
Medical*Online
4) Zamorano JL, Lancellotti P, Munoz DR, et al ; ESC Scientific Document Group : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Euro Heart J 37 : 2768-2801, 2016.
 
5) 坂東泰子 : がん化学療法による高血圧と血管障害の機序と対応. BIO Clinica 34 : 995-998, 2019.
 
6) 田村雄一 : ベッドサイドで使える腫瘍循環器入門. 中外医学社, 東京, 2019, pp.68-73.
 
7) Rini BI, Cohen DP, Lu DR, et al : Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103 : 763-773, 2011.
PubMed
P.33 掲載の参考文献
1) Tamargo J, Caballero R, Delpon E : Cancer chemotherapy and cardiac arrhythmias : a review. Drug Saf 38 : 129-152, 2015.
PubMed
2) Pickham D, Eric Helfenbein E, Shinn JA, et al : How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. J Electrocardiol 43 : 572-576, 2010.
 
P.37 掲載の参考文献
1) Jaiswal S, Natarajan P, Silver AJ, et al : Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 377 : 111-121, 2017.
PubMed
2) Fuster JJ, MacLauchlan S, Zuriaga MA, et al : Clonal hematopoiesis associated with TET2 deThciency accelerates atherosclerosis development in mice. Science 355 : 842-847, 2017.
PubMed
3) Yura Y, Sano S, Walsh K, et al : Clonal Hematopoiesis : A New Step Linking Inflammation to Heart Failure. JACC Basic Transl Sci 5 : 196-207, 2020.
PubMed
4) Coombs CC, Zehir A, Devlin SM, et al : Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell 21 : 374-382, 2017.
PubMed
5) Ferrara N, Hillan KJ, Gerber HP, Novotny W : Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 : 391-400, 2004.
PubMed
6) van der Zee R, Murohara T, Luo Z, et al : Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 95 : 1030-1037, 1997.
PubMed
7) Murohara T, Asahara T, Silver M, et al : Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest 101 : 2567-2578, 1998.
PubMed
8) Murohara T, Horowitz JR, Silver M, et al : Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97 : 99-107, 1998.
PubMed
9) Huang PL, Huang Z, Mashimo H, et al : Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 : 239-242, 1995.
PubMed
10) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19 : 9-42, 2017.
 
11) Moslehi JJ, Deininger M : Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 33 : 4210-4218, 2015.
PubMed
P.39 掲載の参考文献
1) Weatherald J, Chaumais MC, Savale L, et al : Long-term outcomes of dasatinib-induced pulmonary arterial hypertension : a population-based study. Eur Respir J 50 : 1700217, 2017.
PubMed
P.43 掲載の参考文献
1) Lancellotti P, Nkomo VT, Badano LP, et al : Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults : a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26 : 1013-1032, 2013.
PubMed
2) Jaworski C, Mariani JA, Wheeler G, Kaye DM : Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61 : 2319-2328, 2013.
PubMed
3) Gharzai L, Vivek V, Denniston KA, et al : Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer : An Analysis of the Surveillance, Epidemiology, and End Result Database. PLoS One 11 : e0158916, 2016.
 
4) Hayashi Y, Iijima H, Isohashi F, et al : The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer : a retrospective cohort study. BMC Cancer 19 : 195, 2019.
 
5) Beukema JC, van Luijk P, Widder J, et al : Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol 114 : 85-90, 2015.
PubMed
P.48 掲載の参考文献
1) 窓岩清治 : がん患者における静脈血栓塞栓症のマネジメント. 癌と化学療法 44 : 2064-2071, 2017.
Medical*Online
2) Herrmann J : Vascular toxic effects of cancer therapies. Nat Rev Cardiol 17 : 503-522, 2020.
PubMed
P.53 掲載の参考文献
1) von Herbay A, Illes A, Waldherr R, et al : Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer 66 : 587-592, 1990.
PubMed
2) Godbole RH, Saggar R, Kamangar N : Pulmonary tumor thrombotic microangiopathy : a systematic review. Pulm Circ 9 : 1-13, 2019.
PubMed
3) Ogawa A, Yamadori I, Matsubara O, et al : Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med 52 : 1927-1930, 2013.
PubMed
4) Minatsuki S, Miura I, Yao A, et al : Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy. Int Heart J 56 : 245-248, 2015.
PubMed
5) Kubota K, Shinozaki T, Imai Y, et al : Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer. BMJ Case Rep 2017 : bcr2017221032.
PubMed
6) Higo K, Kubota K, Takeda A, et al : Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med 53 : 2595-2599, 2014.
PubMed
7) Fukada I, Araki K, Minatsuki S, et al : Imatinib alleviated pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in a patient with metastatic breast cancer. Clin Breast Cancer 15 : e167-e170, 2015.
 
8) Fukada I, Araki K, Kobayashi K, et al : Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer. Springerplus 5 : 1582, 2016.
PubMed
9) Abe K, Toba M, Alzoubi A, et al : Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 45 : 804-808, 2011.
PubMed
P.56 掲載の参考文献
1) Takayama T, Okura Y, Okada Y, et al : Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis : a single-center study of 113 consecutive cancer patients. Int J Clin Oncol 20 : 872-877, 2015.
PubMed
2) Adler Y, Charron P, Imazio M, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed By : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
3) Fitch MT, Nicks BA, Pariyadath M, et al : Videos in Clinical Medicine. Emergency Pericardiocentesis. N Engl J Med 366 : e17, 2012.
PubMed
4) Imazio M, Gaita F : Diagnosis and treatment of pericarditis. Heart 101 : 1159-1168, 2015.
PubMed
5) Lee PJ, Mallik R : Cardiovascular effects of radiation therapy : practical approach to radiation therapy-induced heart disease. Cardiol Rev 13 : 80-86, 2005.
PubMed
6) Virk SA, Chandrakumar D, Villanueva C, et al : Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 101 : 1619-1626, 2015.
PubMed
P.60 掲載の参考文献
1) Burke A, Virmani R : Tumors of the Heart and Great Vessels. Atlas of Tumor Pathology, 3rd series, fascicle 16, Armed Forces Institute of Pathology, Washington DC, 1996, pp.7-11.
 
2) Amano J, Nakayama J, Yoshimura Y, Ikeda U : Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. Gen Thorac Cardiovasc Surg 61 : 435-447, 2013.
PubMed

実践編

P.65 掲載の参考文献
1) Curigliano G, Lenihan D, Fradley M, et al : Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 31 : 171-190, 2020.
PubMed
2) Key NS, Khorana AA, Kuderer NM, et al : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 38 : 496-520, 2020.
PubMed
3) Kahn SR, Partsch H, Vedantham S, et al ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis : Definition of post-thrombotic syndrome of the leg for use in clinical investigations : a recommendation for standardization. J Thromb Haemost 7 : 879-883, 2009.
PubMed
4) Shiono M, Takahashi S, Kakudo Y, et al : upper arm central venous port implantation : a 6-year single institutional retrospective analysis and pictorial essay of procedures for insertion. PLoS One 9 : e91335, 2014.
PubMed
5) Shiono M, Takahashi S, Takahashi M, et al : Current situation regarding central venous port implantation procedures and complications : a questionnaire-based survey of 11,693 implantations in Japan. Int J Clin Oncol 21 : 1172-1182, 2016.
PubMed
P.69 掲載の参考文献
1) Armenian SH, Lacchetti C, Barac A, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of AdultCancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
P.71 掲載の参考文献
1) Waxman AJ, Clasen S, Hwang WT, et al : Carfilzomib-Associated Cardiovascular Adverse Events : A Systematic Review and Meta-analysis. JAMA Oncol 4 : e174519, 2018.
PubMed
2) Steegmann JL, Baccarani M, Breccia M, et al : European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30 : 1648-1671, 2016.
PubMed
P.75 掲載の参考文献
1) 日本心エコー図学会 : 抗がん剤治療関連心筋障害の診療における心エコー図検査の手引. 2020. http://www.jse.gr.jp/contents/guideline/data/guideline_onco2020-2.pdf
 
2) Plana JC, Galderisi M, Barac A, et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014.
PubMed
P.79 掲載の参考文献
1) Lyon AR, Yousaf N, Battisti NML, et al : Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19 : e447-e458, 2018.
 
2) Mahmood SS, Fradley MG, Cohen JV, et al : Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 : 1755-1764, 2018.
PubMed
日本臨床腫瘍学会編 : がん免疫療法ガイドライン 第2版. 金原出版, 東京, 2019.
 
P.85 掲載の参考文献
1) 庄司正昭, 岩佐健史, 高橋寿由樹ほか : 静脈血栓塞栓症におけるがん拠点病院と総合病院の医療連携 : がん周術期・非周術期のフローチャートの作成. 心臓 51 : 761-768, 2019.
Medical*Online
2) 日本循環器学会ほか : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_ito_h.pdf
 
3) Kakkar AK : Prevention of Venous Thromboembolism in the Cancer Surgical Patient. J Clin Oncol 27 : 4881-4884, 2009.
 
4) Khorana AA, Noble S, Lee AYY, et al : Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism : Guidance From the SSC of the ISTH. J Thromb Haemost 16 : 1891-1894, 2018.
PubMed
5) Kearon C, Akl EA, Ornelas J, et al : Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest 149 : 315-352, 2016.
 
6) Fermann GJ, Erkens PMG, Prins MH, et al : Treatment of Pulmonary Embolism With Rivaroxaban : Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study. Acad Emerg Med 22 : 299-307, 2015.
PubMed
7) Obokata M, Kane GC, Sorimachi H, et al : Noninvasive evaluation of pulmonary artery pressure during exercise : the importance of right atrial hypertension. Eur Respir J 55 : 1901697, 2020.
 
P.89 掲載の参考文献
1) Muller MC, Cervantes F, Hjorth-Hansen H, et al : Ponatinib in chronic myeloid leukemia (CML) : Consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol 120 : 52-59, 2017.
 
2) Montani D, Bergot E, Gunther S, et al : Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125 : 2128-2137, 2012.
PubMed
3) Edahiro Y, Takaku T, Hakuoh K, et al : Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy : a single-center retrospective study. Rinsho Ketsueki 58 : 2213-2218, 2017.
 
4) Minami M, Arita T, Iwasaki H, et al : Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol 177 : 578-587, 2017.
PubMed
5) Shah NP, Wallis N, Farber HW, et al : Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90 : 1060-1064, 2015.
PubMed
6) Zamorano JL, Lancelloti P, Rodriguez MD, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
7) Giles FJ, Mauro MJ, Hong F, et al : Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy : a retrospective cohort analysis. Leukemia 27 : 1310-1315, 2013.
PubMed
8) Chai-Adisaksopha C, Lam W, Hillis C, et al : Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors : a meta-analysis. Leuk Lymphoma 57 : 1300-1310, 2016.
PubMed
9) Cirmi S, Abd AE, Letinier L, et al : Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia : An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers 12 : 826, 2020.
 
10) Moslehi JJ, Deininger M : Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 33 : 4210-4218, 2015.
PubMed
11) Caocci G, Mulas O, Abruzzese E, et al : Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol 37 : 296-302, 2019.
PubMed
12) Schlenk RF, Dohner K : Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 16 : 98-104, 2009.
PubMed
13) Cortes JE, Khaled S, Martinelli G, et al : Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R) : a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20 : 984-997, 2019.
 
14) Perl AE, Martinelli G, Cortes JE, et al : Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 381 : 1728-1740, 2019.
 
15) Brown JR, Moslehi J, O'Brien S, et al : Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 102 : 1796-1805, 2017.
PubMed
16) Gribben JG, Bosch F, Cymbalista F, et al : Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy : European recommendations for clinical practice. Br J Haematol 180 : 666-679, 2018.
PubMed
P.92 掲載の参考文献
1) Zamorano JL, Lancellotti P, Munoz DR, et al : 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines : The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19 : 9-42, 2017.
 
2) Armenian SH, Lacchetti C, Barac A, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
3) Felker GM, Thompson RE, Hare JM, et al : Underlying Causes and Long-Term Survival in Patients With Initially Unexplained Cardiomyopathy. N Engl J Med 342 : 1077-1084, 2000.
PubMed
4) Armenian SH, Mertens L, Slorach C, et al : Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer 124 : 850-857, 2018.
PubMed
P.95 掲載の参考文献
1) Bringhen S, Milan A, Ferri C, et al : Cardiovascular adverse events in modern myeloma therapy-Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica 103 : 1422-1432, 2018.
PubMed
2) Palumbo A, Rajkumar SV, Dimpoulos MA, et al : Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 : 414-423, 2008.
 
3) Plummer C, Driessen C, Szabo Z, Mateos MV : Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J 9 : 26, 2019.
PubMed
4) Bahlis NJ, Lazarus HM : Multiple myeloma-associated AL amyloidosis : is a distinctive therapeutic approach warranted? Bone Marrow Transplant 38 : 7-15, 2006.
PubMed
5) Bever KM, Masha LI, Sun F, et al : Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica 101 : 86-90, 2016.
PubMed
6) Falk RH, Comenzo RL, Skinner M : The systemic amyloidoses. N Engl J Med 337 : 898-909, 1997.
PubMed
P.99 掲載の参考文献
1) Armenian SH, Lacchetti C, Barac A, et al : Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35 : 893-911, 2017.
 
2) Curigliano G, Cardinale D, Suter T, et al : Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy : ESMO Clinical Practice Guidelines. Ann Oncol 23 : vii155-166, 2012.
PubMed
3) 眞鍋恵理子, 川口展子, 石黒洋 : 抗HER2療法に伴う副作用とその対策. 日本臨牀 75 : 351-357, 2017.
Medical*Online
P.102 掲載の参考文献
1) Zamorano JL, Lancellotti P, Munoz DR, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eurn Herat J 37 : 2768-2801, 2016.
 
2) Upadhrasta S, Elias H, Patel K, Zhengc L : Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med 5 : 6-14, 2019.
 
3) Fuchs CS, Tomasek J, Yong CJ, et al : Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 : 31-39, 2014.
PubMed
P.106 掲載の参考文献
1) Okura Y, Ozaki K, Tanaka H, et al : The impending epidemic of cardiovascular diseases in patients with cancer in Japan. Circ J 83 : 2191-2202, 2019.
PubMed
2) Ohashi Y, I keda M, Kunitoh H, et al : Venous thromboembolism in cancer patients : report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol 50 : 1246-1253, 2020.
 
3) 日本循環器学会ほか : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf
 
4) Nishimoto Y, Yamashita Y, Kim K, et al : Risk Factors for Major Bleeding During Anticoagulation Therapy in Cancer-Associated Venous Thromboembolism-From the COMMAND VTE Registry. Circ J 84 : 2006-2014, 2020.
PubMed
5) Strongman H, Gadd S, Matthews A, et al : Medium and Long-Term Risks of Specific Cardiovascular Diseases in Survivors of 20 Adult Cancers : A Population-Based Cohort Study Using Multiple Linked UK Electronic Health Records Databases. Lancet 394 : 1041-1054, 2019.
PubMed
P.109 掲載の参考文献
1) 日本肝臓学会編 : 肝癌診療ガイドライン 2017年版, 金原出版, 東京, 2017.
 
2) レンビマ(R) 適正使用ガイド : エーザイ, 東京.
 
3) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 : 1894-1905, 2020.
PubMed
4) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 : 282-296, 2019.
 
5) Bruix J, Qin S, Merle P, et al : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 : 56-66, 2017.
PubMed
6) 胆道癌診療ガイドライン作成委員会編 : 胆道癌診療ガイドライン 改訂第3版, 医学図書出版, 東京, 2019.
 
7) 日本膵臓学会編 : 膵癌診療ガイドライン 2019年版, 金原出版, 東京, 2019.
 
8) 岡田武規, 森脇香莉, 大橋紀彦ほか : 進行膵癌の化学療法中に急性心筋梗塞を発症した1例. 心臓 46 : 511-516, 2014.
Medical*Online
9) Frere C, Bournet B, Gourgou S, et al : Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology 158 : 1346-1358, 2020.
PubMed
P.111 掲載の参考文献
1) Curigliano G, Lenihan D, Fradley M, et al : Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 31 : 171-190, 2020.
PubMed
2) Leduc C, Antoni D, Charloux A, et al : Comorbidities in the management of patients with lung cancer. Eur Respir J 49 : 1601721, 2017.
PubMed
3) Janssen-Heijnen MLG, van Erning FN, De Ruysscher DK, et al : Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 26 : 902-907, 2015.
PubMed
4) Gornik HL, Gerhard-Herman M, Beckman JA : Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 23 : 5211-5216, 2005.
PubMed
5) Kato R, Hayashi H, Chiba Y, et al : Prognostic Impact of Minimal Pericardial Effusion in Patients With Advanced Non-small-cell Lung Cancer. Clin Lung Cancer 18 : e449-e455, 2017.
PubMed
6) Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S : Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. J Clin Med 9 : 1268, 2020.
PubMed
7) Salem JE, Manouchehri A, Moey M, et al : Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol 19 : 1579-1589, 2018.
 
P.114 掲載の参考文献
1) Aishima K, Yoshimoto Y : Screening strategy using sequential serum D-dimer assay for the detection and prevention of venous thromboembolism after elective brain tumor surgery. Br J Neurosurg 27 : 348-354, 2013.
 
2) Nalluri SR, Chu D, Keresztes R, et al : Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients : a meta-analysis. JAMA 300 : 2277-2285, 2008.
PubMed
P.117 掲載の参考文献
1) Brose MS, Nutting CM, Jarzab B, et al : Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer : a randomised, double-blind, phase 3 trial. Lancet 384 : 319-328, 2014.
PubMed
2) Schlumberger M, Tahara M, Wirth LJ, et al : Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372 : 621-630, 2015.
PubMed
3) Wells SA, Robinson BG, Gagel RF : Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer : a randomized, double-blind phase III trial. J Clin Oncol 30 : 134-141, 2012.
PubMed
4) Tahara M : Management of recurrent or metastatic thyroid cancer. ESMO Open 3 : e000359, 2018.
 
P.120 掲載の参考文献
1) Moslehi JJ : Cardiovascular Toxic Effects of Targeted Cancer Therapies ; N Engl J Med 375 : 1457-1467, 2016.
PubMed
2) Salem JE, Manouchehri A, Moey M, et al : Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors : An Observational, Retrospective, Pharmacovigilance Study. Lancet Oncol 19 : 1579-1589, 2018.
 
P.122 掲載の参考文献
1) Sakon M, Maehara Y, Yoshikawa H, Akaza H : Incidence of venous thromboembolism following major abdominal surgery : a multi-center, prospective epidemiological study in Japan. J Thromb Haemost 4 : 581-586, 2006.
PubMed
2) 佐藤豊実 : 婦人科悪性腫瘍と血栓塞栓症. ACTA OBST GYNAEC JPN 66 : 2024-2028, 2014.
 
P.126 掲載の参考文献
1) Greenlee RT, Goodman MT, Lynch CF, et al : The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep 125 : 28-43, 2010.
PubMed
2) Gatta G, van der Zwan JM, Casali PG, et al : Rare cancers are not so rare : the rare cancer burden in Europe. Eur J Cancer 47 : 2493-2511, 2011.
 
3) 国立がん研究センターがん対策情報センター : 希少がん対策ワークショップ報告書, 2014.
 
4) Leja MJ, Shah DJ, Reardon MJ : Primary cardiac tumors. Tex Heart Inst J 38 : 261-262, 2011.
PubMed
5) 日本整形外科学会監修, 日本整形外科学会診療ガイドライン委員会/軟部腫瘍診療ガイドライン策定委員会編 : 軟部腫瘍診療ガイドライン 2020 改訂第3版. 南江堂, 東京, 2020.
 
6) Tanaka K, Mizusawa J, Fukuda H, et al : Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45 : 555-561, 2015.
PubMed
7) Shantakumar S, Olsen M, Vo TT, et al : Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol 8 : 53-59, 2016.
PubMed
8) Doherty GJ, Davidson D, Wong HH, Hatcher HM : Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma. Anticancer Drugs 30 : 110-115, 2019.
PubMed
9) van der Graaf WT, Blay JY, Chawla SP, et al : Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 : 1879-1886, 2012.
PubMed
10) Lebedinsky C, Gomez J, Park YC, et al : Trabectedin has a low cardiac risk profile : a comprehensive cardiac safety analysis. Cancer Chemother Pharmacol 68 : 1223-1231, 2011.
 
11) Smith LA, Cornel ius VR, Plummer CJ, et al : Cardiotoxicity of anthracycline agents for the treatment of cancer : systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10 : 337, 2010.
 
12) Tap WD, Wagner AJ, Schoffski P, et al : Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas : The ANNOUNCE Randomized Clinical Trial. JAMA 323 : 1266-1276, 2020.
PubMed
13) Jones RL, Wagner AJ, Kawai A, et al : Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial. Annals of Oncology 30 : v685-v686, 2019.
 
14) Kangelaris KN, Sapru A, Calfee CS, et al : fie association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury. Chest 141 : 1160-1169, 2012.
 
15) Berger M, Amini-Adle M, Maucort-Boulch D, et al : Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients : A retrospective analysis. Cancer Med 9 : 2611-2620, 2020.
PubMed
16) Larkin J, Chiarion-Sileni V, Gonzalez R, et al : Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 381 : 1535-1546, 2019.
PubMed
17) Lenders JW, Eisenhofer G, Mannelli M, et al : Phaeochromocytoma. Lancet 366 : 665-675, 2005.
PubMed
18) Nakane M, Takahashi S, Sekine I, et al : Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 14 : 1449-1451, 2003.
PubMed
19) Zhang R, Gupta D, Albert SG : Pheochromocytoma as a reversible cause of cardiomyopathy : Analysis and review of the literature. Int J Cardiol 249 : 319-323, 2017.
PubMed
20) Santos JRU, Brofferio A, Viana B, et al : Catecholamine-Induced Cardiomyopathy in Pheochromocytoma : How to Manage a Rare Complication in a Rare Disease? Horm Metab Res 51 : 458-469, 2019.
 
P.130 掲載の参考文献
1) Zamorano JL, Lancellotti P, Munoz DR, et al : 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines : The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC), Eur Heart J 37 : 2768-2801, 2016.
 
2) Herrmann J, Lerman A, Sandhu NP, et al : Evaluation and management of patients with heart disease and cancer : cardio-oncology. Mayo Clin Proc 89 : 1287-1306, 2014.
PubMed
P.134 掲載の参考文献
1) Johnson DB, Balko JM, Compton ML, et al : Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375 : 1749-1755, 2016.
PubMed
2) Mahmood SS, Fradley MG, Cohen JV, et al : Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 : 1755-1764, 2018.
PubMed
3) Salem JE, Manouchehri A, Moey M, et al : Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study. Lancet Oncol 19 : 1579-1589, 2018.
 
4) Hu JR, Florido R, Lipson EJ, et al : Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115 : 854-868, 2019.
PubMed
5) Brahmer JR, Lacchetti C, Schneider BJ, et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American society of clinical oncology clinical practice guideline. J Clin Oncol 36 : 1714-1768, 2018.
 
6) Lyon AR, Yousaf N, Battisti NML, et al : Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19 : e447-e458, 2018.
 
P.137 掲載の参考文献
1) Cohen JB, Geara AS, Hogan JJ, Townsend RR : Hypertension in Cancer Patients and Survivors : Epidemiology, Diagnosis, and Management. JACC 1 : 238-251, 2019.
PubMed
2) Doerfler RM, Diamantidis CJ, Wagner LA, et al : Usability testing of a sick-day protocol in CKD. Clin J Am Soc Nephrol 14 : 583-585, 2019.
PubMed
3) 日本高血圧学会高血圧治療ガイドライン作成委員会編 : 高血圧治療ガイドライン 2019. ライフサイエンス出版, 東京, 2019.
 
4) Wright JT Jr, Bakris G, Greene T, et al : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial. JAMA 288 : 2421-2431, 2002.
PubMed
5) Li XY, Sun JF, Hu SQ : The renin-angiotensin system blockers as adjunctive therapy for cancer : a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci 21 : 1375-1383, 2017.
 
P.144 掲載の参考文献
1) Pabinger I, Thaler J, Ay C, et al : Biomarkers for prediction of venous thromboembolism in cancer. Blood 122 : 2011-2018, 2013.
PubMed
2) Carrire M, Abou-Nassar K, Mallick R, et al : Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380 : 711-719, 2019.
 
3) 日本循環器学会 : 肺血栓塞栓症および深部静脈血栓症の診断,治療, 予防に関するガイドライン (2017年改訂版). 2018. http://www.j-circ.or.jp/guideline/pdf/JCS2017_ito_h.pdf
 
4) Hiraide M, Shiga T, Minowa Y et al : Identification of Risk Factors for Venous Thromboembolism and Evaluation of Khorana Venous Thromboembolism Risk Assessment in Japanese Lung Cancer Patients. J Cardiol 75 : 110-114, 2020.
PubMed
5) Khorana AA : Venous Thromboembolism and Prognosis in Cancer. Thromb Res 125 : 490-493, 2010.
PubMed
6) Timp JF, Braekkan SK, Versteeg HH, et al : Epidemiology of cancer-associated venous thrombosis. Blood 122 : 1712-1723, 2013.
PubMed
7) Konstantinides SV, Meyer G, Becattini C, et al : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal 41 : 543-603, 2019.
 
8) 加藤元嗣, 上堂文也, 掃本誠治ほか : 日本消化器内視鏡学会抗血栓薬服用者に対する消化器内視鏡診療ガイドライン 追補 2017. Gastroenterol Endosc 59 : 1547-1558, 2017.
 
9) Khorana AA, Kuderer NM, Culakova E, et al : Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 : 4902-4907, 2008.
PubMed
10) Barbar S, Noventa F, Rossetto V, et al : A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism : the Padua Prediction Score. J Thromb Haemost 8 : 2450-2457, 2010.
 
11) Caprini JA : Thrombosis risk assessment as a guide to quality patient care. Dis Mon 51 : 70-78, 2005.
PubMed
12) Key NS, Khorana AA, Kuderer NM, et al : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 38 : 496-520, 2020.
PubMed
13) Kearon C, Akl EA, Ornelas J, et al : Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest 149 : 315-352, 2016.
 
14) Farge D, Frere C, Connors JM, et al : 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20 : e566-e581, 2019.
PubMed
15) Khorana AA, Noble S, Lee AYY, et al : Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism : guidance from the SSC of the ISTH. J Thromb Haemost 16 : 1891-1894, 2018.
PubMed
P.148 掲載の参考文献
1) Kantarjian H, Giles F, Wunderle L, et al : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 : 2542-2551, 2006.
 
2) Kinoshita T, Yuzawa H, Natori K, et al : Early electrocardiographic indices for predicting chronic doxorubicin-induced cardiotoxicity. J Cardiol 77 : 388-394, 2021.
PubMed
3) Armenian SH, Lacchetti C, Barac A, et al : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 : 893-911, 2017.
 
P.153 掲載の参考文献
1) Negishi T, Miyazaki S, Negishi K : Echocardiography and Cardio-Oncology. Heart Lung Circ 28 : 1331-1338, 2019.
PubMed
2) Negishi T, Thavendiranathan P, Negishi K, et al : Rationale and Design of the Strain Surveillance of Chemotherapy for improving Cardiovascular Outcomes (SUCCOUR) Trial. JACC Cardiovasc Imaging 11 : 1098-1105, 2018.
PubMed
P.155 掲載の参考文献
1) Riddell E, Lenihan D : The role of cardiac biomarkers in cardio-oncology. Curr Probl Cancer 42 : 375-385, 2018.
PubMed
2) Cardinale D, Colombo A, Sandri MT, et al : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 : 2474-2481, 2006.
PubMed
P.159 掲載の参考文献
1) Altena R, Perik PJ, van Veldhuisen DJ, et al : Cardiovascular toxicity caused by cancer treatment : strategies for early detection. Lancet Oncol 10 : 391-399, 2009.
PubMed
2) Fallah-Rad N, Lytwyn M, Fang T, et al : Delayed Contrast Enhancement Cardiac Magnetic Resonance Imaging in Trastuzumab Induced Cardiomyopathy. J Cardiovasc Magn Reson 10 : 5, 2008.
PubMed
3) Neilan TG, Coelho-Filho OR, Shah RV, et al : Myocardial Extracellular Volume by Cardiac Magnetic Resonance Imaging in Patients Treated With Anthracycline-Based Chemotherapy. Am J Cardiol 111 : 711-722, 2013.
 
4) Kitagawa K, Takeda K, Saito K, et al : Differences in fatty acid metabolic disorder between ischemic myocardium and doxorubicin-induced myocardial damage : assessment using BMIPP dynamic SPECT with analysis by the Rutland method. J Nucl Med 43 : 1286-1294, 2002.
 
P.163 掲載の参考文献
1) Bristow MR, Mason JW, Billingham ME, Daniels JR : Doxorubicin cardiomyopathy : evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88 : 168-175, 1978.
PubMed
2) Bonaca MP, Olenchock BA, Salem JE, et al : Myocarditis in the Setting of Cancer Therapeutics : Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation 140 : 80-91, 2019.
PubMed
3) Hardy T, Yin M, Chavez JA, et al : Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings : a case report. Cardiovasc Pathol 46 : 107202, 2020.
PubMed
4) Baban B, Liu JY, Qin X, et al : Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models : Interaction with GADD153. PLoS One 10 : e0124059, 2015.
PubMed
P.166 掲載の参考文献
1) Righini M, Perrier A, De Moerloose P, Bounameaux H : D-Dimer for venous thromboembolism diagnosis : 20 years later. J Thromb Haemost 6 : 1059-1071, 2008.
PubMed
2) Wells PS, Hirsh J, Anderson DR, et al : Accuracy of clinical assessment of deep-vein thrombosis. Lancet 345 : 1326-1330, 1995.
PubMed
3) Key NS, Khorana AA, Kuderer NM, et al : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 38 : 496-520, 2020.
PubMed
P.169 掲載の参考文献
1) 家子正裕 : 直接経口凝固薬 (DOAC) のモニタリング. Vita 33 : 47-53, 2016.
 
P.172 掲載の参考文献
1) Herrmann J : Vascular toxic effects of cancer therapies. Nat Rev Cardiol 17 : 503-522, 2020.
PubMed
2) 日本循環器学会ほか : 血管機能の非侵襲的評価法に関するガイドライン. 2013. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2013_yamashina_h.pdf
 
3) Tanaka A, Tomiyama H, Maruhashi T, et al : Physiological Diagnostic Criteria for Vascular Failure. Hypertension 72 : 1060-1071, 2018.
PubMed
P.178 掲載の参考文献
1) Okura Y, Ozaki K, Tanaka H, et al : The impending epidemic of cardiovascular diseases in patients with cancer in Japan. Circ J 83 : 2191-2202, 2019.
PubMed
P.181 掲載の参考文献
1) Barac A, Murtagh G, Carver JR, et al : Cardiovascular health of patients with cancer and cancer survivors : a roadmap to the next level. J Am Coll Cardiol 65 : 2739-2746, 2015.
 
2) Yeh ET : Onco-cardiology : the time has come. Tex Heart Inst J 38 : 246-247, 2011.
PubMed
3) Lyon AR, Dent S, Stanway S, et al : Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies : a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020〔Online ahead of print〕
 
4) Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19 : 9-42, 2017.
 
5) Plana JC, Galderisi M, Barac A, et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014.
PubMed
6) Demissei BG, Adusumalli S, Hubbard R, et al : Cardiology involvement in patients with breast cancer treated with trastuzumab. JACC : CardioOncology 2 : 179-189, 2020.
PubMed
7) Patnaik JL, Byers T, DiGuiseppi C, et al : Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer : a retrospective cohort study. Breast Cancer Res 13 : R64, 2011.
PubMed
P.187 掲載の参考文献
1) Gilchrist SC, Barac A, Ades PA, et al : Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors : A Scientific Statement From the American Heart Association. Circulation 139 : e997-e1012, 2019.
PubMed
2) D'Ascenzi F, Anselmi F, Fiorentini C, et al : The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology. Eur J Prev Cardiol 2019〔Online ahead of print〕
 
P.190 掲載の参考文献
1) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers ver 5.0. Children's Oncology Group. http://www.survivorshipguidelines.org
 
2) JPLSG長期フォローアップ委員会長期フォローアップガイドライン作成ワーキンググループ編 : 小児がん治療後の長期フォローアップガイドライン. 医薬ジャーナル社, 東京, 2013.
 
P.193 掲載の参考文献
1) 総合的な思春期・若年成人世代のがん対策のあり方に関する研究班編 : 医療従事者が知っておきたいAYA世代サポートガイド. 金原出版, 東京, 2018.
 
2) Katanoda K, Shibata A, Matsuda A, et al : Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. Jpn J Clin Oncol 47 : 762-771, 2017.
 
3) Bleyer A : Young adult oncology : the patients and their survival challenges. CA Cancer J Clin 57 : 242-255, 2007.
 
4) 厚生労働省 : 厚生労働科学研究費補助金 (がん対策推進総合研究事業) 「総合的な思春期・若年成人 (AYA) 世代のがん対策のあり方に関する研究」 (研究代表者 : 堀部敬三, 研究分担者 : 小原 明). 平成28 年度総括・分担研究報告書. 2017.
 
P.195 掲載の参考文献
1) NCCN Clinical Practice Guideline in Oncology : Older adult oncology. Version 1. 2020-February 7, 2020. https://www.nccn.org/professionals/physician_gls/default.aspx
 
2) 日本老年医学会 : ACP推進に関する提言. 2019. https://www.jpn-geriat-soc.or.jp/
 
P.198 掲載の参考文献
1) Thompson KA : Pregnancy and cardiomyopathy after anthracyclines in childhood. Front Cardiovasc Med 5 : 14, 2018.
PubMed
2) 日本循環器学会・日本心不全学会合同ガイドライン : 心筋症診療ガイドライン (2018 年改訂版). 2019. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf
 
3) Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al ; ESC Scientific Document Group : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal 39 : 3165-3241, 2018.
 
4) Bar J, Davidi O, Goshen Y, et al : Pregnancy outcome in women treated with doxorubicin for childhood cancer. Am J Obstet Gynecol 189 : 853-857, 2003.
PubMed
5) Chait-Rubinek L, Mariani JA, Goroncy N, et al : A retrospective evaluation of risk of peripartum cardiac dysfunction in survivors of childhood, adolescent and young adult malignancies. Cancers 11 : 1046, 2019.
 
6) van Dalen EC, van del Pal HJH, van den Bos C, et al : Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur J Cancer 42 : 2549-2553, 2006.
 
7) Hines MR, Mulrooney DA, Hudson MM, et al : Pregnancy-associated cardiomyopathy in survivors of childhood cancer. J Cancer Surviv 10 : 113-121, 2016.
PubMed
8) Thompson KA, Hildebrandt MAT, Ater JL, et al : Cardiac outcomes with pregnancy after cardiotoxic therapy for childhood cancer. J Am Coll Cardiol 69 : 594-595, 2017.
 

付録

P.206 掲載の参考文献
1) Shelburne N, Simonds NI, Adhikari B, et al : Changing Hearts and Minds : Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep 21 : 9, 2019.
PubMed
P.214 掲載の参考文献
1) Daimon M, Watanabe H, Abe Y, et al : Normal values of echocardiographic parameters in relation to age in a healthy Japanese population : the JAMP study. Circ J 72 : 1859-1866, 2008.
 
2) Seo Y, Ishizu T, Ieda M, et al : Elderly Japanese Standard Data of Echocardiography ; From J-LONG study. J Echocardiogr 2020 Apr 18〔Online ahead of print〕
 
3) Lang RM, Badano LP, Mor-Avi V, et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39.e14, 2015.
 
4) Nagueh SF, Smiseth OA, Appleton CP, et al : Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 : 277-314, 2016.
PubMed
5) Kuznetsova T, Herbots L, Richart T, et al : Left ventricular strain and strain rate in a general population. European Heart Journal 29 : 2014-2023, 2008.
 
P.226 掲載の参考文献
1) Yeh ET : Onco-cardiology : the time has come. Tex Heart Inst J 38 : 246-247, 2011.
PubMed
2) Albini A, Pennesi G, Donatelli F, et al : Cardiotoxicity of anticancer drugs : the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102 : 14-25, 2010.
PubMed
3) Yeh ET, Tong AT, Lenihan DJ, et al : Cardiovascular complications of cancer therapy : diagnosis, pathogenesis, and management. Circulation 109 : 3122-3131, 2004.
PubMed
4) Yeh ET, Bickford CL : Cardiovascular complications of cancer therapy : Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 : 2231-2247, 2009.
PubMed
5) Chang HM, Moudgil R, Scarabelli T, et al : Cardiovascular complications of cancer therapy : best practices in diagnosis, prevention, and management : Part 1. J Am Coll Cardiol 70 : 2536-2551, 2017.
PubMed
6) Chang HM, Okwuosa TM, Scarabelli T, et al : Cardiovascular complications of cancer therapy : best practices in diagnosis, prevention, and management-Part 2. J Am Coll Cardiol 70 : 2552-2565, 2017.
PubMed
7) Lyman GH, Khorana AA, Falanga A, et al : American Society of Clinical Oncology guideline : recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 : 5490-5505, 2007.
 
8) Key NS, Khorana AA, Kuderer NM, et al : Venous thromboembolism prophylaxis and treatment in patients with cancer : ASCO clinical practice guideline update. J Clin Oncol 38 : 496-520, 2020.
PubMed
9) Cardio-Oncology HP : https://cardiooncologyjournal.biomedcentral.com/
 
10) 2019 GCOS Proceedings : https://cardiooncology.onlinejacc.org/events/GCOS2019
 
11) Lenihan DJ, Fradley MG, Dent S, et al : Proceedings from the Global Cardio-Oncology Summit. The top 10 priorities to actualize for cardio oncology. J Am Coll Cardiol Cardio Oncol 1 : 256-272, 2019.
 
12) Curigliano G, Cardinale D, Suter T, et al : Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy : ESMO clinical practice guidelines. Ann Oncol 23 : vii155-166, 2012.
PubMed
13) Curigliano G, Lenihan D, Fradley M, et al : Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 31 : 171-190, 2020.
PubMed
14) Lancellotti P, Nkomo VT, Badano LP, et al : Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults : a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26 : 1013-1032, 2013.
PubMed
15) Plana JC, Galderisi M, Barac A, et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014.
PubMed
16) Shelburne N, Adhikari B, Brell J, et al : Cancer treatment-related cardiotoxicity : current state of knowledge and future research priorities. J Natl Cancer Inst 106 : dju232, 2014.
PubMed
17) Herrmann J, Lerman A, Sandhu NP, et al : Evaluation and management of patients with heart disease and cancer : Cardio-Oncology. Mayo Clin Proc 89 : 1287-1306, 2014.
PubMed
18) Zamorano JL, Lancellotti P, Munoz DR, et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
19) Iliescu CA, Grines CL, Herrmann J, et al : SCAI Expert consensus statement : Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista). Catheter and Cardiovasc Interv 87 : E202-223, 2016.
PubMed
20) Armenian SH, Lacchetti C, Barac A, et al : Prevention and monitoring of cardiac dysfunction in survivors of adult cancers : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35 : 893-911, 2017.
 
21) Lopez-Fernandez T, Garcia AM, Beltran AS, et al : Cardioonco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed) 70 : 474-486, 2017.
 
22) Brahmer JR, Lacchetti C, Schneide BJ, et al : Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36 : 1714-1768, 2018.
 
23) Anker MS, Hadzibegovic S, Lena A, et al : Recent advances in cardio-oncology : a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'. ESC Heart Fail 6 : 1140-1148, 2019.
PubMed
24) JACC Cardio Oncology HP : https://cardiooncology.onlinejacc.org/content/1/2/145
 
25) Campia U, Moslehi JJ, Amiri-Kordestani L, et al : Cardiooncology : vascular and metabolic perspectives : a scientific statement from the American Heart Association. Circulation 139 : e579-e602, 2019.
PubMed
26) Thompson JA, Schneider BJ, Brahmer J, et al : Management of immunotherapy related toxicities, version 1. 2019. J Natl Compr Canc Netw 17 : 255-289, 2019.
PubMed
27) Thompson JA, Schneider BJ, Brahmer J, et al : Management of immunotherapy-related toxicities, version 1. 2020. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 18 : 230-241, 2020.
 
28) Gilchrist SC, Barac A, Ades PA, et al : Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors : a scientific statement from the American Heart Association. Circulation 139 : e997-e1012, 2019.
PubMed
29) Selby P, Popescu R, Lawler M, et al : The value and future developments of multidisciplinary team cancer care. Am Soc Clin Oncol Educ Book 39 : 332-340, 2019.
PubMed
30) Rassaf T, Totzeck M, Backs J, et al : Onco-cardiology : consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol 2020. doi : 10.1007/s00392-020-01636-7〔Online ahead of print〕
 

書評

最近チェックした商品履歴

Loading...